e-Therapeutics plc Starts Second Phase I Cancer Trial of ETS2101
9/12/2012 10:29:18 AM
OXFORD & NEWCASTLE, England--(BUSINESS WIRE)--e-Therapeutics plc (AIM: ETX) announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James’s University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle. It complements an investigator-led phase I study of ETS2101 in brain cancer that began in San Diego, California during June.